Khaled F. Debbabi, M. S. Bashandy, Sami A. Al-Harbi
Mar 5, 2017
Citations
1
Influential Citations
11
Citations
Quality indicators
Journal
Journal of Molecular Structure
Abstract
Abstract This article describes the synthesis of some novel sulfonamides having biologically active pyridine 21–28 . Starting with 4-(1-(2-(2-cyanoacetyl)hydrazono)ethyl)- N -ethyl- N -methylbenzenesulfonamide (2) , which was prepared from condensation of acetophenone derivative 1 with 2-cyanoacetohydrazide. Interaction of compound 2 with different aldehydes namely 4-fluorobenzaldehyde, 4-hydroxybenzaldehyde and 4- N , N -dimethylbenzaldehyde afforded the corresponding hydrazono-ethyl- N -ethyl- N -methylbenzene sulfonamides 18–20 respectively, which when reacted with malononitrile and ethyl cyanoacetate afforded compounds 21–26 respectively. These compounds 21–26 can be prepared by another reaction route by interaction of compounds 2 with arylidine malononitrile and arylidine ethyl cyanoacetate in refluxing dioxane in the presence of trimethylamine as catalyst. Interaction of compound 2 with malononitrile and ethyl cyanoacetate afforded oxopyridine derivatives 27 and 28 respectively. All the new prepared compounds were evaluated for their antitumor activities against the cell lines MCF-7 in comparison with the reference drug Doxorubicin using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay. Compounds 25 , 21 , 23 with SI values of 9.72, 9.71, 8.81 respectively, exhibited better activity than doxorubicin (Dox) as a reference drug with SI value of 8.49. In addition, compounds 25 , 27 and 22 exhibited anti-bacterial activity against gram-negative bacteria ( Klebsiella pneumoniae ) with inhibition zones 22.6, 20.3 and 19.3 mm respectively, which were more active than gentamicin as a reference drug with inhibition zone 17.3 mm. Molecular Operating Environment (MOE) performed virtual screening using molecular docking studies of the synthesized compounds. The results indicated that some synthesized compounds suitable inhibitor against dihydrofolate reductase (DHFR) enzyme (PDB SD: 4DFR) with further modification.